Company intelligence / Profile preview
AKSO Biopharmaceutical, Inc.
Los Angeles, California, United Statesaksobio.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
AB001, an engineered high-affinity soluble BCMA decoy receptor, has demonstrated effectiveness in inhibiting Multiple Myeloma and Diffuse Large B Cell Lymphoma in preclinical studies with impressive safety profile in non-human primates[8][10]
- Therapeutic areas
- OncologyRare DiseasesImmunologyOtherNephrology
- Modalities
- Protein therapeuticsBispecific biologicsAntibody-drug conjugatesRecombinant fusion proteins
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Huadong Medicine (for AB002 in Asia-Pacific excluding Japan)Chime Biologics (CDMO services)
Beyond the preview
Go deeper on AKSO Biopharmaceutical, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AKSO Biopharmaceutical, Inc..